[CAS NO. 112811-59-3] Gatifloxacin
PRODUCTS SPECIFICATIONS [112811-59-3]
DESCRIPTION [112811-59-3]
Overview
| MDL | MFCD00895399 |
|---|---|
| Molecular Weight | 375.39 |
| Molecular Formula | C19H22FN3O4 |
| SMILES | CC1NCCN(C2=C(F)C=C3C(N(C4CC4)C=C(C(O)=O)C3=O)=C2OC)C1 |
2 Publications Citing Use of MCE
Summary
Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases ( IC 50 =13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase ( IC 50 =0.109 μg/ml) [1] . Gatifloxacin can be used to treat bacterial conjunctivitis in vivo.
IC50 & Target
|
Quinolone
|
Topoisomerase II 36.7 μM (IC 50 ) |
In Vitro
Gatifloxacin is against
S. aureus
MS5935 topoisomerase IV,
E. coli
NIHJ JC-2 DNA gyrase and HeLa cell topoisomerase II with IC
50
values of 13.8 μg/ml, 0.109 μg/ml, and 265 μg/ml, respectively
[1]
.
Gatifloxacin is against
S. aureus
MS5935 topoisomerase IV,
E. coli
NIHJ JC-2 DNA gyrase and HeLa cell topoisomerase II with MIC values of 0.05 μg/ml, 0.0063 μg/ml, and 122 μg/ml, respectively
[1]
.
Gatifloxacin exhibits antibacterial activities for wild-type strains (MS5935, MS5952, MR5867 and MR6009) the first-, second-, third-, and fourth-step mutants with MIC values of 0.05 to 0.10 μg/ml, 0.20 μg/ml, 1.56 to 3.13 μg/ml, 1.56 to 6.25 μg/ml, and 50 to 200 μg/ml, respectively. Gatifloxacin displays the most potent activity against the second- and third-step mutants (MS5952, MR5867 and MR6009) except for the second-step mutant of strain MS5935
[2]
.
Gatifloxacin has potent activity against norA transformant NY12 (MIC, 0.39 μg/ml)
[2]
.
Gatifloxacin (20-100 μM; 72 hours) significantly decreases insulin content to 60% at Day 1, and continues to be reduced to 50.1% and 44.7% at Day 3 by 20 μM and 100 μM gatifloxacin, respectively
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Gatifloxacin (subcutaneous injection; 100 mg/kg; 3 times a day; 30 days) significantly decreases the number of lesions in mouse footpad with
Nocardia brasiliensis
[4]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Female BALB/c mice with Nocardia brasiliensis in the right hind footpad. |
| Dosage: | 100 mg/kg |
| Administration: | Subcutaneous injection; 3 times a day; 30 days |
| Result: | Reduced the production of lesions in mice. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01218737 | Federal University of São Paulo|Allergan |
Ocular Infection and Inflammation
|
January 2009 | Phase 3 |
| NCT00396084 | National Institute of Allergy and Infectious Diseases (NIAID) |
Tuberculosis
|
February 10, 2004 | Phase 1|Phase 2 |
| NCT00335231 | Queen´s University |
Endophthalmitis
|
June 2006 | Not Applicable |
| NCT01421693 | Oxford University Clinical Research Unit, Vietnam|University of Oxford|Patan Academy of Health Sciences, Nepal|Patan Hospital, Nepal|Civil Hospital, Nepal |
Enteric Fever|Typhoid Fever
|
September 2011 | Phase 4 |
| NCT00410891 | Stanford University |
Intravitreous|Injections
|
July 2008 | Phase 4 |
| NCT00874887 | Allergan |
Anti-biotic Resistance
|
March 2009 | Phase 4 |
| NCT00464438 | Allergan |
Bacterial Conjunctivitis
|
June 2007 | Phase 4 |
| NCT00347828 | Ophthalmic Consultants of Boston|Allergan |
Eye Infection|Infection
|
June 2006 | Phase 4 |
| NCT00824070 | Bausch & Lomb Incorporated |
Cataract Extraction
|
February 2009 | Phase 1 |
| NCT00569881 | Donnenfeld, Eric, M.D. |
Corneal Epithelial Wound Healing
|
January 2007 | |
| NCT00216385 | Institut de Recherche pour le Developpement|World Health Organization|European Commission |
Tuberculosis
|
January 2005 | Phase 3 |
| NCT00407017 | Innovative Medical |
Cataract Surgery
|
Phase 4 | |
| NCT00905762 | Bausch & Lomb Incorporated |
Healthy
|
March 2009 | Phase 1 |
| NCT00414011 | Walter Reed Army Medical Center |
Epithelium, Corneal
|
Not Applicable | |
| NCT01330355 | Bausch & Lomb Incorporated |
Bacterial Conjunctivitis
|
May 2011 | Phase 3 |
| NCT00892918 | Meir Medical Center |
Primary Pterygium
|
June 2009 | Not Applicable |
| NCT00518089 | Allergan |
Bacterial Conjunctivitis
|
February 2008 | Phase 3 |
| NCT00433225 | Innovative Medical |
Macula Thickening
|
Phase 4 | |
| NCT00651586 | Allergan |
Acute Bacterial Corneal Ulcers|Bacterial Keratitis
|
October 2003 | Phase 2 |
| NCT03578276 | Carolina Eyecare Physicians, LLC|Science in Vision|Imprimis Pharmaceuticals, Inc. |
Cataract
|
June 22, 2018 | Phase 4 |
| NCT00509873 | Allergan |
Bacterial Conjunctivitis
|
August 2007 | Phase 3 |
| NCT00703313 | Santen Inc. |
Healthy
|
May 2008 | Phase 4 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Solvent & Solubility
DMSO : 2 mg/mL ( 5.33 mM ; Need ultrasonic)
H 2 O : 1 mg/mL ( 2.66 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.6639 mL | 13.3195 mL | 26.6390 mL |
| 5 mM | 0.5328 mL | 2.6639 mL | 5.3278 mL |
| 10 mM | --- | --- | --- |
References
- [1] Takei M, et al. Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases.Antimicrob Agents Chemother. 1998 Oct;42(10):2678-81.
- [2] Fukuda H, et al. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus. Antimicrob Agents Chemother. 1998 Aug;42(8):1917-22.
- [3] Yamada C, et al. Gatifloxacin acutely stimulates insulin secretion and chronically suppresses insulin biosynthesis. Eur J Pharmacol. 2006 Dec 28;553(1-3):67-72. Epub 2006 Sep 28.
Synonyms
